Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024PRNewsWire • 04/11/24
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsPRNewsWire • 04/09/24
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferencePRNewsWire • 02/26/24
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialPRNewsWire • 02/08/24
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsPRNewsWire • 01/31/24
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024PRNewsWire • 01/24/24
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferencePRNewsWire • 01/04/24
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetPRNewsWire • 12/19/23
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationPRNewsWire • 12/12/23
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023PRNewsWire • 11/30/23
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferencePRNewsWire • 10/09/23
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressPRNewsWire • 09/05/23
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)PRNewsWire • 08/30/23
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 08/28/23
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesPRNewsWire • 08/01/23
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of DirectorsPRNewsWire • 07/24/23
Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq RulesPRNewsWire • 07/14/23
Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq RulesPRNewsWire • 07/12/23
Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in BostonPRNewsWire • 06/01/23